侯 芸, 王华庆, 付 凯, 刘贤明, 张会来, 钱正子, 李兰芳, 周世勇, 崔秀珍, 郝希山. CTVP与CTOP方案治疗280 例非霍奇金淋巴瘤临床疗效分析[J]. 中国肿瘤临床, 2010, 37(18): 1065-1068. DOI: 10.3969/j.issn.1000-8179.2010.18.010
引用本文: 侯 芸, 王华庆, 付 凯, 刘贤明, 张会来, 钱正子, 李兰芳, 周世勇, 崔秀珍, 郝希山. CTVP与CTOP方案治疗280 例非霍奇金淋巴瘤临床疗效分析[J]. 中国肿瘤临床, 2010, 37(18): 1065-1068. DOI: 10.3969/j.issn.1000-8179.2010.18.010
shu
HOU Yun, WANG Huaqing, FU Kai, LIU Xianming, ZHANG Huilai, QIAN Zhengzi, LI Lanfang, ZHOU Shiyong, CUI Xiu-zhen, HAO Xishan. Comparison of the Therapeutic Effects of CTVP and CTOP Regimens asInitialTreatmen tfor  Non-Hodgkin's Lymphoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 37(18): 1065-1068. DOI: 10.3969/j.issn.1000-8179.2010.18.010
Citation: HOU Yun, WANG Huaqing, FU Kai, LIU Xianming, ZHANG Huilai, QIAN Zhengzi, LI Lanfang, ZHOU Shiyong, CUI Xiu-zhen, HAO Xishan. Comparison of the Therapeutic Effects of CTVP and CTOP Regimens asInitialTreatmen tfor  Non-Hodgkin's Lymphoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 37(18): 1065-1068. DOI: 10.3969/j.issn.1000-8179.2010.18.010
shu

CTVP与CTOP方案治疗280 例非霍奇金淋巴瘤临床疗效分析

Comparison of the Therapeutic Effects of CTVP and CTOP Regimens asInitialTreatmen tfor  Non-Hodgkin's Lymphoma

    摘要
  • 摘要: 目的：比较含长春地辛（VDS ）的CTVP方案与含长春新碱（VCR ）的CTOP方案治疗初治非霍奇金淋巴瘤（NHL ）的近期疗效、远期生存及不良反应。方法：采用两种方案治疗初治NHL 患者共280 例，CTVP组162 例，CTOP组118 例。结果：两组患者临床特征指标相似（P>0.05）。 可评价疗效272 例，两组有效率分别为73.13% 和72.32% ，临床获益率分别为91.88% 和90.18%（P>0.05）。 骨髓抑制、胃肠道反应、乏力、外周神经毒性和脱发为主要不良反应。CTVP组外周神经毒性的发生率低于CTOP组（14.81% ：31.36% ，P<0.05）。 中位随访时间32个月（2～71个月），两组5 年生存率分别为43.2% 和22.3%（P<0.05）。 结论：采用含VDS 的CTVP方案治疗初治NHL 疗效较好，毒性较低，远期生存率较高，值得临床进一步研究。

     

    Abstract: Objective:To compare the efficacy and toxicity of CTVP (with VDS) and CTOP (with VCR) regimens as an initial treatment for Non-Hodgkin Lymphoma. Methods:From January2000to December 2005, 288 patients with Non-Hodg-kin Lymphoma were treated in Tianjin Cancer Hospital with combined chemotherapy, including CTVP and CTOP, among which 162 were treated by CTVP and 118 by CTOP regimen. The rate of response, toxicity and long-term survival for the 2 regimens were analyzed retrospectively. Results: The clinical characteristics of the 2 groups were quite similar (P>0.05). A total of 272 patients were eligible. The response rates for CTVP and CTOP were73.13% and 72.32%, the clinical benefit rates were 91.88% and 90.18%, respectively (P>0.05). Major toxicity was myelosuppression, GI toxicity, fatigue, neurotoxic -ity and alopecia. Incidence of neurotoxicity was lower in the CTVP group than in the CTOP group (14.81% vs.31.36%,P<0.05). Median follow-up was 32months (ranging from 2 to 71months). The 5-year overall survival rates for the CTVP and CTOP groups were 43.2％and 22.3％, respectively ( P<0.05). Conclusion:VDS in the CTVP regimen may be more effective as an initial treatment for Non-Hodgkin lymphoma, with lower toxicity and better long-term surviva1. A randomized clinical trial is required to confirm these results.

     

    • HTML全文
    • 参考文献(0)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回